Details The technical summary data is suggesting a short of APLS if it tests 36.47 with a downside target of 29.74. We should ...

Shares of NASDAQ APLS opened at $29.98 on Thursday ... the director now owns 100,000 shares of the company’s stock, valued at ...

APLS has been the topic of a number of other reports ... valued at approximately $3,623,000. The trade was a 0.00 % decrease ...

Apellis Pharmaceuticals (NASDAQ:APLS) shares fell sharply on Tuesday after the Waltham, Massachusetts-based biotech reported lower-than-expected Q3 2024 financials as U.S. net sales from its eye ...

Short interest in Apellis Pharmaceuticals Inc (NASDAQ:APLS) increased during the last reporting period, rising from 15.26M to 21.09M. This put 23.91% of the company's publicly available shares short.

Apellis Pharmaceuticals Inc (NASDAQ:APLS) reported a 7% quarter-over-quarter growth in commercial development for its product, with 84,500 vials shipped. The company achieved a significant ...

The market expects Apellis Pharmaceuticals, Inc. (APLS) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2024.

Apellis Pharmaceuticals, Inc. (APLS) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $1.17 per share a year ago.

Evercore ISI analyst Umer Raffat maintained a Buy rating on Apellis Pharmaceuticals (APLS – Research Report) today. The company’s shares closed yesterday at $27.71. According to TipRanks ...